Product logins

Find logins to all Clarivate products below.


Population Health Management in Type 2 Diabetes: What Does This Approach Mean for Specific Diabetes Brands? | Physician & Payer Forum | US | 2014

Population health management (PHM) represents one of the long-term goals of the healthcare industry: building upon the patient-centered medical home concept to provide proactive support to a defined patient population in an attempt to address preventable behaviors that drive up healthcare costs. Through process improvement aided by technology, PHM helps with clinical decision support, thus improving the quality of care as well as patient safety. In diabetes, PHM is an attractive target for the following reasons: its ability to stratify patient populations, the disease’s high prevalence and costs, concerns over patient noncompliance, the risk of hospitalization associated with the disease, and the presence of defined treatment algorithms.

PHM is geared toward high-risk individuals and changes in physician compensation (partly tied to the proliferation of accountable care organizations) are translating into changes in prescribing behavior. As the use of PHM becomes more ingrained in physicians’ practice behavior, specific therapies will gain market share at the expense of others.

Related Market Assessment Reports

Report
Hemophilia A – Current Treatment – Current Treatment: Physician Insights – Hemophilia A with Inhibitors (US)
Development of neutralizing antibodies against factor VIII replacement is the most significant clinical complication in hemophilia A, necessitating specialized and often high-cost management…
Report
Major Depressive Disorder (DSM-V) – Access & Reimbursement – Access & Reimbursement – Major Depressive Disorder (US)
Numerous drugs from multiple drug classes are used as monotherapies and/or adjunctive therapies to treat major depressive disorder (MDD). Early-line treatment is dominated by generically available…
Report
Malignant Melanoma – Unmet Need – Unmet Need – BRAF Wild-Type, Unresectable or Metastatic Malignant Melanoma (US/EU)
Treatment for BRAF wild-type unresectable or metastatic melanoma has been largely shaped by the successive approvals of immune checkpoint inhibitors. Anti-PD-1 agents such as Keytruda (Merck & Co…
Report
Systemic Lupus Erythematosus – Unmet Need – Unmet Need – Moderate to Severe Systemic Lupus Erythematosus (US/EU)
Systemic lupus erythematosus (SLE) is an autoimmune disease that can affect different organ systems of the body and manifest in a wide range of clinical symptoms, from general fatigue to serious…
Report
Systemic Lupus Erythematosus | Unmet Need | Moderate to Severe Systemic Lupus Erythematosus | US/EU | 2024
Systemic lupus erythematosus (SLE) is an autoimmune disease that can affect different organ systems of the body and manifest in a wide range of clinical symptoms, from general fatigue to serious…